GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Innopharmax Inc (ROCO:4172) » Definitions » Revenue

Innopharmax (ROCO:4172) Revenue : NT$34.59 Mil (TTM As of Jun. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Innopharmax Revenue?

Innopharmax's revenue for the six months ended in Jun. 2024 was NT$23.17 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2024 was NT$34.59 Mil. Innopharmax's Revenue per Share for the six months ended in Jun. 2024 was NT$0.24. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was NT$0.36.

Warning Sign:

Innopharmax Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Innopharmax was -34.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was -34.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was -18.50% per year. During the past 10 years, the average Revenue per Share Growth Rate was -6.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Innopharmax's highest 3-Year average Revenue per Share Growth Rate was 173.90% per year. The lowest was -34.30% per year. And the median was 0.45% per year.


Innopharmax Revenue Historical Data

The historical data trend for Innopharmax's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innopharmax Revenue Chart

Innopharmax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 84.89 136.88 48.06 29.13 46.07

Innopharmax Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.69 14.45 34.65 11.42 23.17

Competitive Comparison of Innopharmax's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Innopharmax's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innopharmax's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Innopharmax's Revenue distribution charts can be found below:

* The bar in red indicates where Innopharmax's Revenue falls into.



Innopharmax Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$34.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innopharmax  (ROCO:4172) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Innopharmax Revenue Related Terms

Thank you for viewing the detailed overview of Innopharmax's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Innopharmax Business Description

Traded in Other Exchanges
N/A
Address
No. 22, Lane 478, Ruiguang Road, 9th Floor, Neihu District, Taipei, TWN, 11492
Innopharmax Inc is a Taiwan based specialty pharmaceutical company. It is focused on the development and commercialization of products for the treatment of oncology and specialty. The company's products include anti-infection agents, contrast agents, oncology agents, immunological agents, drugs for rare diseases and others.

Innopharmax Headlines

No Headlines